235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1755)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer (564)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (6)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (69)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 21 of 21
Condition: Addiction / Opioids
Investigator: Felipe Castillo, Md
Status: Currently Recruiting
Looking for participants aged 18 to 55 who have trouble with heroin or other opiates to participate in a month-long research study at Columbia University Irving Medical Center evaluating the relationship between brain tasks and memory.
Condition: Addiction / Opioids
Investigator: Dana Sacco, MD
Status: Currently Recruiting
The purpose of this research study is to evaluate how commonly drug overdoses in our community involve fentanyl and xylazine. We know that often drugs such as heroin, oxycontin, and even cocaine and methamphetamine, actually contain these additives, even though the person buying the drugs is not aware.
Condition: Addiction / Alcohol
Investigator: A. Benjamin Srivastava, MD
Status: Currently Recruiting
Columbia University Medical Center is recruiting individuals ages 21-55 who are seeking treatment for alcohol problems to participate in a research study involving treatment. For your participation, you'll receive treatment with disulfiram (brand name Antabuse) at no cost. You be treated with disulfiram for approximately 13 weeks and undergo brain…
Condition: Addiction / Opioids
Investigator: Rachel Luba, PhD
Status: Currently Recruiting
Columbia University Medical Center is recruiting individuals ages 18-65 who are seeking treatment for opioid use disorder to participate in a research treatment study. For your participation, you'll receive treatment with buprenorphine (either sublingual or injectable) at no cost. Participants will complete an overnight inpatient stay to start…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Have an Opioid Use Disorder? We need your help for an inpatient clinical research study! Help the New York State Psychiatric Institute research better treatment options for those with opioid use disorder.You could earn up to $12,017.00.You must meet the following criteria: - Age 18 -59 years old- Have opioid use disorder- Be currently taking an oral daily…
Condition: Addiction / Opioids
Investigator: Jermaine Jones, PhD
Status: Closed
Healthy Black and Latino heroin users (male and female ages 25-55) are needed for a research study assessing the relationship between heroin use and cellular aging. The study involves a single visit to the New York State Psychiatric Institute, and consists of questionnaires and the collection of a blood sample for genetic testing. The visit will take about…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Addiction / Opioids
Investigator: Mina Rizk, MD
Status: Closed
This research study uses MRI scans to compare the effect of two medications on suicidal thoughts and brain activity in people who have opioid use disorder. We hope to develop a better understanding of how well these two medications help depression and suicidal thoughts. You may qualify if you have opioid use disorder and suicidal thoughts. Participation…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Condition: Addiction / Alcohol
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with HIV and HCV drink less. The goal of the study is to compare…
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
Condition: Addiction / Opioids
Investigator: Frances Levin, MD
Status: Closed
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…